Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NORA DANIEL

Allopathic & Osteopathic Physicians Pediatrics

NPI
1720183106
CMS profile
32608
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$114.62

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $114.62 1

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
SANOFI-AVENTIS U.S. LLC $114.62 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NORA DANIEL

NPI 1720183106 · CMS profile ID 32608

Allopathic & Osteopathic Physicians / Pediatrics

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1720183106?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NORA DANIEL, NPI 1720183106, CMS profile ID 32608. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1720183106?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). NORA DANIEL, NPI 1720183106, CMS profile ID 32608. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1720183106?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
NORA DANIEL, NPI 1720183106, CMS profile ID 32608, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1720183106?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $114.62 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
SANOFI-AVENTIS U.S. LLC $114.6204/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139598723 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $17.80 1
PY2022 $140.81 2
PY2023 $1,353.47 10
PY2024 $114.62 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2022, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,328,285.04 535
PY2024 Principal investigator $517,981.68 120
PY2023 Principal investigator $685,808.52 880
PY2022 Principal investigator $908,256.60 1,978

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

120 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,699.68 12/31/2024 Non-covered Recipient Entity
THE GLAUCOMA CARE CENTER OF NEW
3070-301-001 Ph3 Pediatric LTS (M21-478) No dispute reported 06/30/2026 1100765993
Principal investigator 1 ABBVIE INC. $8,098.00 12/19/2024 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1100761780
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,898.00 12/16/2024 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
ITI-007-421 No dispute reported 06/30/2026 1143156663
Principal investigator 1 ABBVIE INC. $9,810.00 11/27/2024 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1100756727
Principal investigator 1 ABBVIE INC. $9,475.00 11/06/2024 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1100752145
Principal investigator 1 Genentech, Inc. $6,342.00 10/30/2024 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133400508
Principal investigator 1 Genentech, Inc. $4,228.00 10/23/2024 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133400502
Principal investigator 1 Genentech, Inc. $43,337.00 10/11/2024 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133400506
Principal investigator 1 ABBVIE INC. $15,503.00 10/03/2024 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1100745852
Principal investigator 1 Genentech, Inc. $2,114.00 10/02/2024 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133400504
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,575.00 10/02/2024 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
ITI-007-421 No dispute reported 06/30/2026 1143137531
Principal investigator 1 Neurocrine BioSciences Inc. $804.00 10/02/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150274238
Principal investigator 1 Neurocrine BioSciences Inc. $723.60 10/02/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150274544
Principal investigator 1 Genentech, Inc. $63,420.00 09/06/2024 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133400498
Principal investigator 1 Neurocrine BioSciences Inc. $3,144.00 09/04/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150270473
Principal investigator 1 Neurocrine BioSciences Inc. $3,144.00 09/04/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150270475
Principal investigator 1 Neurocrine BioSciences Inc. $3,144.00 09/04/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150270477
Principal investigator 1 Neurocrine BioSciences Inc. $3,144.00 09/04/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150270479
Principal investigator 1 Neurocrine BioSciences Inc. $3,144.00 09/04/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150270481
Principal investigator 1 Neurocrine BioSciences Inc. $3,144.00 09/04/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150270483
Principal investigator 1 Neurocrine BioSciences Inc. $3,144.00 09/04/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150270485
Principal investigator 1 Neurocrine BioSciences Inc. $3,144.00 09/04/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150270487
Principal investigator 1 Neurocrine BioSciences Inc. $1,407.60 09/04/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150273161
Principal investigator 1 Neurocrine BioSciences Inc. $804.00 09/04/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150274222
Principal investigator 1 Neurocrine BioSciences Inc. $804.00 09/04/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150274224
Principal investigator 1 Neurocrine BioSciences Inc. $804.00 09/04/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150274226
Principal investigator 1 Neurocrine BioSciences Inc. $804.00 09/04/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150274228
Principal investigator 1 Neurocrine BioSciences Inc. $804.00 09/04/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150274230
Principal investigator 1 Neurocrine BioSciences Inc. $804.00 09/04/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150274232
Principal investigator 1 Neurocrine BioSciences Inc. $804.00 09/04/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150274234
Principal investigator 1 Neurocrine BioSciences Inc. $804.00 09/04/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150274236
Principal investigator 1 ABBVIE INC. $16,528.00 08/16/2024 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1100736758
Principal investigator 1 Genentech, Inc. $1,057.00 08/16/2024 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133400500
Principal investigator 1 Neurocrine BioSciences Inc. $1,931.00 08/09/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150272335
Principal investigator 1 Neurocrine BioSciences Inc. $1,931.00 08/09/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150272337
Principal investigator 1 Neurocrine BioSciences Inc. $1,931.00 08/09/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150272339
Principal investigator 1 Neurocrine BioSciences Inc. $1,931.00 08/09/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150272341
Principal investigator 1 Neurocrine BioSciences Inc. $1,931.00 08/09/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150272343
Principal investigator 1 Neurocrine BioSciences Inc. $1,351.70 08/09/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150273244
Principal investigator 1 ABBVIE INC. $35,605.00 07/16/2024 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1100729950
Principal investigator 1 ABBVIE INC. $23,830.00 07/03/2024 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1100725332
Principal investigator 1 Neurocrine BioSciences Inc. $1,931.00 07/03/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150272345
Principal investigator 1 Neurocrine BioSciences Inc. $1,931.00 07/03/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150272347
Principal investigator 1 Neurocrine BioSciences Inc. $1,931.00 07/03/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150272349
Principal investigator 1 Neurocrine BioSciences Inc. $1,544.80 07/03/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150272867
Principal investigator 1 Genentech, Inc. $14,880.00 06/12/2024 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133400496
Principal investigator 1 Neurocrine BioSciences Inc. $2,356.00 06/07/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150271445
Principal investigator 1 Neurocrine BioSciences Inc. $2,120.40 06/07/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150271923
Principal investigator 1 ABBVIE INC. $22,681.00 06/05/2024 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1100721318
Principal investigator 1 ABBVIE INC. $21,263.00 05/08/2024 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1100715916
Principal investigator 1 Neurocrine BioSciences Inc. $2,356.00 05/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150271431
Principal investigator 1 Neurocrine BioSciences Inc. $2,356.00 05/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150271433
Principal investigator 1 Neurocrine BioSciences Inc. $2,356.00 05/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150271435
Principal investigator 1 Neurocrine BioSciences Inc. $2,356.00 05/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150271437
Principal investigator 1 Neurocrine BioSciences Inc. $2,356.00 05/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150271439
Principal investigator 1 Neurocrine BioSciences Inc. $2,356.00 05/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150271441
Principal investigator 1 Neurocrine BioSciences Inc. $2,356.00 05/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150271443
Principal investigator 1 Neurocrine BioSciences Inc. $1,931.00 05/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150272325
Principal investigator 1 Neurocrine BioSciences Inc. $1,931.00 05/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150272327
Principal investigator 1 Neurocrine BioSciences Inc. $1,931.00 05/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150272329
Principal investigator 1 Neurocrine BioSciences Inc. $1,931.00 05/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150272331
Principal investigator 1 Neurocrine BioSciences Inc. $1,931.00 05/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150272333
Principal investigator 1 Neurocrine BioSciences Inc. $679.35 05/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150274726
Principal investigator 1 Neurocrine BioSciences Inc. $503.00 05/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150275225
Principal investigator 1 Neurocrine BioSciences Inc. $503.00 05/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150275227
Principal investigator 1 Neurocrine BioSciences Inc. $503.00 05/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150275229
Principal investigator 1 Neurocrine BioSciences Inc. $503.00 05/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150275231
Principal investigator 1 Neurocrine BioSciences Inc. $503.00 05/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150275233
Principal investigator 1 Neurocrine BioSciences Inc. $503.00 05/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150275235
Principal investigator 1 Neurocrine BioSciences Inc. $503.00 05/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150275237
Principal investigator 1 Neurocrine BioSciences Inc. $503.00 05/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150275239
Principal investigator 1 Neurocrine BioSciences Inc. $503.00 05/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150275241
Principal investigator 1 Neurocrine BioSciences Inc. $503.00 05/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150275243
Principal investigator 1 ABBVIE INC. $500.00 05/02/2024 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1100715488
Principal investigator 1 Neurocrine BioSciences Inc. $150.00 04/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150276744
Principal investigator 1 Neurocrine BioSciences Inc. $3,431.00 04/05/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150270225
Principal investigator 1 Neurocrine BioSciences Inc. $3,431.00 04/05/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150270227
Principal investigator 1 Neurocrine BioSciences Inc. $3,431.00 04/05/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150270229
Principal investigator 1 Neurocrine BioSciences Inc. $2,317.00 04/05/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150271501
Principal investigator 1 Neurocrine BioSciences Inc. $2,317.00 04/05/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150271503
Principal investigator 1 Neurocrine BioSciences Inc. $2,317.00 04/05/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150271505
Principal investigator 1 Neurocrine BioSciences Inc. $2,317.00 04/05/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150271507
Principal investigator 1 Neurocrine BioSciences Inc. $1,931.00 04/05/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150272315
Principal investigator 1 Neurocrine BioSciences Inc. $1,931.00 04/05/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150272317
Principal investigator 1 Neurocrine BioSciences Inc. $1,931.00 04/05/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150272319
Principal investigator 1 Neurocrine BioSciences Inc. $1,931.00 04/05/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150272321
Principal investigator 1 Neurocrine BioSciences Inc. $1,931.00 04/05/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150272323
Principal investigator 1 Neurocrine BioSciences Inc. $1,547.15 04/05/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150272865
Principal investigator 1 Neurocrine BioSciences Inc. $503.00 04/05/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150275205
Principal investigator 1 Neurocrine BioSciences Inc. $503.00 04/05/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150275207
Principal investigator 1 Neurocrine BioSciences Inc. $503.00 04/05/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150275209
Principal investigator 1 Neurocrine BioSciences Inc. $503.00 04/05/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150275211
Principal investigator 1 Neurocrine BioSciences Inc. $503.00 04/05/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150275213
Principal investigator 1 Neurocrine BioSciences Inc. $503.00 04/05/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150275215
Principal investigator 1 Neurocrine BioSciences Inc. $503.00 04/05/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150275217
Principal investigator 1 Neurocrine BioSciences Inc. $503.00 04/05/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150275219
Principal investigator 1 Neurocrine BioSciences Inc. $503.00 04/05/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150275221
Principal investigator 1 Neurocrine BioSciences Inc. $503.00 04/05/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150275223
Principal investigator 1 ABBVIE INC. $1,754.00 04/04/2024 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1100710892
Principal investigator 1 Genentech, Inc. $1,569.00 03/13/2024 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133400492
Principal investigator 1 Neurocrine BioSciences Inc. $3,431.00 03/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150270207
Principal investigator 1 Neurocrine BioSciences Inc. $3,431.00 03/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150270209
Principal investigator 1 Neurocrine BioSciences Inc. $3,431.00 03/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150270211
Principal investigator 1 Neurocrine BioSciences Inc. $3,431.00 03/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150270213
Principal investigator 1 Neurocrine BioSciences Inc. $3,431.00 03/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150270215
Principal investigator 1 Neurocrine BioSciences Inc. $3,431.00 03/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150270217
Principal investigator 1 Neurocrine BioSciences Inc. $3,431.00 03/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150270219
Principal investigator 1 Neurocrine BioSciences Inc. $3,431.00 03/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150270221
Principal investigator 1 Neurocrine BioSciences Inc. $3,431.00 03/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150270223
Principal investigator 1 Neurocrine BioSciences Inc. $2,317.00 03/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150271489
Principal investigator 1 Neurocrine BioSciences Inc. $2,317.00 03/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150271491
Principal investigator 1 Neurocrine BioSciences Inc. $2,317.00 03/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150271493
Principal investigator 1 Neurocrine BioSciences Inc. $2,317.00 03/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150271495
Principal investigator 1 Neurocrine BioSciences Inc. $2,317.00 03/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150271497
Principal investigator 1 Neurocrine BioSciences Inc. $2,317.00 03/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150271499
Principal investigator 1 Neurocrine BioSciences Inc. $1,020.40 03/08/2024 Non-covered Recipient Entity
Links Clinical Trials LLC
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150273722
Principal investigator 1 ABBVIE INC. $6,805.00 03/07/2024 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1100706498
Principal investigator 1 Genentech, Inc. $12,552.00 02/07/2024 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133400490
Principal investigator 1 ABBVIE INC. $12,017.00 02/01/2024 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1100702340
Principal investigator 1 Genentech, Inc. $3,500.00 01/12/2024 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133400494